ATE417103T1 - Zellulärer rezeptor für hiv-1 vpr essentiell zum g2-m übergang des zellzyklus - Google Patents
Zellulärer rezeptor für hiv-1 vpr essentiell zum g2-m übergang des zellzyklusInfo
- Publication number
- ATE417103T1 ATE417103T1 AT98952230T AT98952230T ATE417103T1 AT E417103 T1 ATE417103 T1 AT E417103T1 AT 98952230 T AT98952230 T AT 98952230T AT 98952230 T AT98952230 T AT 98952230T AT E417103 T1 ATE417103 T1 AT E417103T1
- Authority
- AT
- Austria
- Prior art keywords
- hvip
- nucleic acid
- acid molecules
- encode
- nucleotide sequence
- Prior art date
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title 1
- 230000022131 cell cycle Effects 0.000 title 1
- 230000001413 cellular effect Effects 0.000 title 1
- 230000007704 transition Effects 0.000 title 1
- 101000860047 Homo sapiens COP9 signalosome complex subunit 6 Proteins 0.000 abstract 14
- 102000043472 human COPS6 Human genes 0.000 abstract 14
- 150000007523 nucleic acids Chemical class 0.000 abstract 7
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 230000000295 complement effect Effects 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000003259 recombinant expression Methods 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002853 nucleic acid probe Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/949,202 US6060587A (en) | 1996-01-29 | 1997-10-10 | Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE417103T1 true ATE417103T1 (de) | 2008-12-15 |
Family
ID=25488736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98952230T ATE417103T1 (de) | 1997-10-10 | 1998-10-09 | Zellulärer rezeptor für hiv-1 vpr essentiell zum g2-m übergang des zellzyklus |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6060587A (de) |
| EP (1) | EP1021464B1 (de) |
| JP (1) | JP2001522582A (de) |
| KR (2) | KR100707316B1 (de) |
| AT (1) | ATE417103T1 (de) |
| AU (1) | AU745235B2 (de) |
| CA (1) | CA2306440A1 (de) |
| DE (1) | DE69840333D1 (de) |
| WO (1) | WO1999019359A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045333B1 (en) * | 1998-01-16 | 2006-05-16 | Incyte Corporation | Human protease molecules |
| US6448078B1 (en) * | 1998-10-09 | 2002-09-10 | The Trustees Of The University Of Pennsylvania | Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle |
| CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| PT1141315E (pt) * | 1998-12-31 | 2008-05-05 | Novartis Vaccines & Diagnostic | Polipéptidos do envelope (env) de hiv modificados |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| JP2002533124A (ja) * | 1998-12-31 | 2002-10-08 | カイロン コーポレイション | Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成 |
| US20020107193A1 (en) * | 2000-11-09 | 2002-08-08 | Glazner Gordon W. | Therapeutic uses for IP3 receptor-mediated calcium channel modulators |
| US6673894B1 (en) | 2001-02-27 | 2004-01-06 | Nucleus Remodeling, Incorporated | Inhibitor of cell proliferation and methods of use thereof |
| DK1397520T3 (da) * | 2001-05-25 | 2006-03-27 | Univ Pennsylvania | HIV-1 Vpr-interaktioner med mitokondriel apoptoseinducerende faktor samt fremgangsmåder til anvendelse heraf |
| WO2002100317A2 (en) | 2001-05-25 | 2002-12-19 | The Trustees Of The University Of Pennsylvania | Targeted particles and methods of using the same |
| EP2292772A1 (de) * | 2001-07-05 | 2011-03-09 | Novartis Vaccines and Diagnostics, Inc. | HIV Impfung mit für ein HIV Polypeptid kodierender DNS und einem HIV Polypeptid |
| WO2003004620A2 (en) * | 2001-07-05 | 2003-01-16 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| EP1427806A4 (de) * | 2001-08-31 | 2006-04-26 | Chiron Corp | Antigene hiv-typ-b-polypeptide codierende polynukleotide, polypeptide und verwendungen davon |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| HRP20180607T1 (hr) | 2011-06-10 | 2019-04-05 | Oregon Health & Science University | Glikoproteini i rekombinantni vektori cmv |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
| EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
| EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
| WO2025010715A1 (zh) * | 2023-07-13 | 2025-01-16 | 深圳华大生命科学研究院 | 工程生物遏制系统及方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5001230A (en) * | 1988-02-18 | 1991-03-19 | Schering Corporation | T cell activation markers |
| US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5780220A (en) * | 1994-05-19 | 1998-07-14 | Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting HIV replication |
| US5763190A (en) * | 1994-09-21 | 1998-06-09 | The Trustees Of The University Of Pennsylvania | Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein |
| US6203979B1 (en) * | 1998-01-16 | 2001-03-20 | Incyte Pharmaceuticals, Inc. | Human protease molecules |
-
1997
- 1997-10-10 US US08/949,202 patent/US6060587A/en not_active Expired - Lifetime
-
1998
- 1998-10-09 DE DE69840333T patent/DE69840333D1/de not_active Expired - Lifetime
- 1998-10-09 EP EP98952230A patent/EP1021464B1/de not_active Expired - Lifetime
- 1998-10-09 KR KR1020007003859A patent/KR100707316B1/ko not_active Expired - Fee Related
- 1998-10-09 JP JP2000515930A patent/JP2001522582A/ja active Pending
- 1998-10-09 AT AT98952230T patent/ATE417103T1/de not_active IP Right Cessation
- 1998-10-09 CA CA002306440A patent/CA2306440A1/en not_active Abandoned
- 1998-10-09 AU AU97980/98A patent/AU745235B2/en not_active Ceased
- 1998-10-09 WO PCT/US1998/021432 patent/WO1999019359A1/en not_active Ceased
- 1998-10-09 KR KR1020067004547A patent/KR100707315B1/ko not_active Expired - Fee Related
-
1999
- 1999-10-13 US US09/418,175 patent/US6172201B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6172201B1 (en) | 2001-01-09 |
| KR100707316B1 (ko) | 2007-04-13 |
| EP1021464A4 (de) | 2002-08-21 |
| CA2306440A1 (en) | 1999-04-22 |
| KR20060024467A (ko) | 2006-03-16 |
| EP1021464B1 (de) | 2008-12-10 |
| JP2001522582A (ja) | 2001-11-20 |
| WO1999019359A8 (en) | 1999-08-05 |
| WO1999019359A1 (en) | 1999-04-22 |
| AU9798098A (en) | 1999-05-03 |
| EP1021464A1 (de) | 2000-07-26 |
| AU745235B2 (en) | 2002-03-14 |
| US6060587A (en) | 2000-05-09 |
| DE69840333D1 (de) | 2009-01-22 |
| KR100707315B1 (ko) | 2007-04-13 |
| WO1999019359A9 (en) | 1999-06-24 |
| KR20010040257A (ko) | 2001-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE417103T1 (de) | Zellulärer rezeptor für hiv-1 vpr essentiell zum g2-m übergang des zellzyklus | |
| Gamarnik et al. | Two functional complexes formed by KH domain containing proteins with the 5'noncoding region of poliovirus RNA. | |
| Allison et al. | Extensive homology among the largest subunits of eukaryotic and prokaryotic RNA polymerases | |
| Blyn et al. | Requirement of poly (rC) binding protein 2 for translation of poliovirus RNA | |
| He et al. | RPA involvement in the damage-recognition and incision steps of nucleotide excision repair | |
| Horikoshi et al. | Cloning and structure of a yeast gene encoding a general transcription initiation factor TFIID that binds to the TATA box | |
| Komine et al. | Genomic organization and physical mapping of the transfer RNA genes in Escherichia coli K12 | |
| Fett et al. | The primary structure of human glutaminyl-tRNA synthetase. A highly conserved core, amino acid repeat regions, and homologies with translation elongation factors | |
| Barker et al. | Methionyl‐tRNA Synthetase from Escherichia coli: Primary Structure of the Active Crystallised Tryptic Fragment | |
| TR200700740T2 (tr) | Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler | |
| AR003423A1 (es) | Anticuerpos monoclonales humanos de alta afinidad especificos de la proteina- f del rsv, celulas eucarioticas transfectadas; secuencia de adn y vector de expresion que lo codifican; metodo que utiliza los anticuerpos; una composicion farmaceutica que los contiene; metodo para detectar rsv y un kit de ensayo. | |
| PT1240325E (pt) | Polipéptidos homólogos de il-17 e il-17r e suas utilizações terapêuticas | |
| WO2002031134A3 (en) | Novel serine protease genes related to dppiv | |
| WO2001038486A3 (en) | Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies | |
| Sauer et al. | Primary structure of the phage P22 repressor and its gene c2 | |
| DE60203692D1 (de) | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen | |
| Johnson et al. | Identification of a plastid-specific ribosomal protein in the 30 S subunit of chloroplast ribosomes and isolation of the cDNA clone encoding its cytoplasmic precursor. | |
| AR023482A1 (es) | Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos | |
| BR0009393A (pt) | Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para a produção do polipeptìdeo, uso de um polipeptìdeo, e, composição detergente | |
| GB9722320D0 (en) | Human cell cycle checkpoint proteins | |
| Severinov et al. | Streptolydigin-resistant mutants in an evolutionarily conserved region of the β′ subunit of Escherichia coli RNA polymerase | |
| Minakhin et al. | Mapping the molecular interface between the σ70 subunit of E. coli RNA polymerase and T4 AsiA | |
| WO1998011234A3 (en) | Human protein kinases | |
| US20200360529A1 (en) | Peptidic materials that traffic efficiently to the cell cytosol and nucleus | |
| DE69632457D1 (de) | Neue menschliche proteine, die cyclin abhängigen kinasen ähneln, sowie methoden zu deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |